2019
Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data
Baecker A, Kim S, Risch HA, Nuckols TK, Wu BU, Hendifar AE, Pandol SJ, Pisegna JR, Jeon CY. Do changes in health reveal the possibility of undiagnosed pancreatic cancer? Development of a risk-prediction model based on healthcare claims data. PLOS ONE 2019, 14: e0218580. PMID: 31237889, PMCID: PMC6592596, DOI: 10.1371/journal.pone.0218580.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic cancerRisk factorsPDAC diagnosisNew-onset diabetes patientsEnd Results (SEER) tumorMonths of claimsUndiagnosed pancreatic cancerClinical risk factorsMultivariable logistic regressionDiagnosis of PDACSex-matched controlsCase-control studyRisk prediction modelHealthcare claims dataSurveillance EpidemiologyResults TumorsDiabetes patientsDuctal adenocarcinomaClaims dataHealthcare claimsEarly detection methodsLogistic regressionCancerDiagnosis
2016
Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study
Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case–control study. Cancer Causes & Control 2016, 27: 1457-1464. PMID: 27817122, DOI: 10.1007/s10552-016-0824-4.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsUse of NSAIDsPopulation-based case-control studyCase-control studyAnti-inflammatory drugsPancreatic cancerProtective effectHistory of NSAIDsUnconditional multivariable logistic regressionSelective COX-2 inhibitorsMultivariable logistic regressionPancreatic cancer riskSex-matched controlsCOX-2 inhibitorsPancreatic cancer studiesStatin useMedication useSmoking statusCancer riskMedication sectionStatinsCancerLogistic regressionMore frequent usersCancer studies